Stock Market & Financial Investment News

News Breaks August 30, 2012 09:10 EDT BMY, SNY NIH says aspirin-clopidogrel no better than aspirin alone for lacunar stroke Aspirin combined with the antiplatelet drug clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination carries a greater risk of gastrointestinal bleeding, according to results of a trial funded by the National Institutes of Health. The NIH stated last night that trial results also point to an overall improvement in stroke management during the past decade. Regardless of whether patients received aspirin alone or the dual therapy, their stroke risk was reduced more than three-fold from what it was 10 years ago. Antiplatelet drugs such as aspirin are routinely prescribed to help prevent new strokes in people with a history of lacunar stroke. The Secondary Prevention of Small Subcortical Strokes trial was designed to determine if adding clopidogrel to aspirin would offer better protection than aspirin alone. The results appear in the Aug. 30th New England Journal of Medicine. They show that the aspirin-clopidogrel combination was about equal to aspirin in reducing the risk of any type of stroke, but it almost doubled the risk of gastrointestinal bleeding. Clopidogrel is marketed by Bristol-Myers Squibb (BMY) and Sanofi (SNY) under the trade name Plavix. News For BMY;SNY From The Last 14 Days Check below for free stories on BMY;SNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. 1 | 2 | all recent news | >> May 22, 2013 16:00 EDT BMY Options Update; May 22, 2013 Subscribe for More Information 10:33 EDT BMY Bristol-Myers jumps after Citi ups rating on cancer potential Subscribe for More Information 10:16 EDT BMY Bristol-Myers spikes higher following upgrade, levels to watch Subscribe for More Information 10:00 EDT BMY On The Fly: Analyst Upgrade Summary Subscribe for More Information 06:05 EDT BMY Bristol-Myers upgraded to Buy from Neutral at Citigroup Subscribe for More Information May 21, 2013 07:44 EDT SNY Sachs Associates to host a forum Subscribe for More Information 07:34 EDT BMY UBS to host a conference Subscribe for More Information 07:24 EDT BMY Global Health Care to host a conference Subscribe for More Information May 20, 2013 17:26 EDT SNY Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement' Subscribe for More Information 11:27 EDT SNY Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva Subscribe for More Information 10:03 EDT BMY Shire advances after report renews takeover speculation Subscribe for More Information 06:30 EDT BMY Leerink estimates Shire takeout value at least $110 per share Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. 06:25 EDT BMY Shire may return cash to thwart takeover, Daily Mail reports Subscribe for More Information May 17, 2013 13:21 EDT BMY Options with increasing implied volatility: CPRT BMY GDI HNZ Subscribe for More Information 08:03 EDT SNY Sanofi reports positive topline results from pivotal Phase III Jakarta study Subscribe for More Information 05:18 EDT SNY Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint Subscribe for More Information May 16, 2013 16:32 EDT BMY Bristol-Myers announces intention to voluntarily delist preferred stock Subscribe for More Information 13:20 EDT BMY Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. 13:14 EDT BMY Bristol-Myers upgraded to Outperform from Market Perform at Leerink Subscribe for More Information 08:55 EDT BMY BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information 1 | 2 | all recent news | >> Sign up for a free trial to see the rest of the stories you've been missing.